{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ecv1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ec_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2021-11-02T16:56:59.021Z","role":"Publisher"},{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ec_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2020-12-15T17:00:00.000Z","role":"Approver"}],"evidence":[{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ec_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:7b995ad3-3545-4ffb-bae2-e48ce9f5b7e8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7b995ad3-3545-4ffb-bae2-e48ce9f5b7e8","type":"Proband","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.674G>T (p.Arg225Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA316566"}},"detectionMethod":"Unknown testing strategy","phenotypeFreeText":"disc pallor","phenotypes":["obo:HP_0200134","obo:HP_0001250","obo:HP_0012758"],"sex":"UnknownEthnicity","variant":{"id":"cggv:d4726234-2fa3-4979-a2fe-8d5fb8605606_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28985901","type":"dc:BibliographicResource","dc:abstract":"Pyridoxine is converted to its biologically active form pyridoxal-5-phosphate (P5P) by the enzyme pyridox(am)ine 5'-phosphate oxidase and serves as a cofactor in nearly 200 reactions in the central nervous system. Pyridox(am)ine 5'-phosphate oxidase deficiency leads to P5P dependent epilepsy, typically a neonatal- or infantile-onset epileptic encephalopathy treatable with P5P or in some cases, pyridoxine. Following identification of retinopathy in a patient with pyridox(am)ine 5'-phosphate oxidase deficiency that was reversible with P5P therapy, we describe the systemic manifestations of pyridox(am)ine 5'-phosphate oxidase deficiency.","dc:creator":"Guerriero RM","dc:date":"2017","dc:title":"Systemic Manifestations in Pyridox(am)ine 5'-Phosphate Oxidase Deficiency."}},"rdfs:label":"Guerriero Patient 2"},{"id":"cggv:d4726234-2fa3-4979-a2fe-8d5fb8605606","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:d4726234-2fa3-4979-a2fe-8d5fb8605606_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:9c7b6724-bb8c-43f5-a84e-df952858d522_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:9c7b6724-bb8c-43f5-a84e-df952858d522","type":"Proband","allele":{"id":"cggv:fc68cfd3-6ee8-4bf5-8ee9-50c0f62bfa4a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.98A>T (p.Asp33Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA316580"}},"detectionMethod":"DNA analysis from the chorionic villus indicated that the foetus was affected","firstTestingMethod":"Other","phenotypeFreeText":"minimal delay","phenotypes":"obo:HP_0001250","sex":"UnknownEthnicity","variant":{"id":"cggv:9ac6f151-3d32-4d6c-90d8-da0eecbc88ca_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fc68cfd3-6ee8-4bf5-8ee9-50c0f62bfa4a"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24645144","type":"dc:BibliographicResource","dc:abstract":"The first described patients with pyridox(am)ine 5'-phosphate oxidase deficiency all had neonatal onset seizures that did not respond to treatment with pyridoxine but responded to treatment with pyridoxal 5'-phosphate. Our data suggest, however, that the clinical spectrum of pyridox(am)ine 5'-phosphate oxidase deficiency is much broader than has been reported in the literature. Sequencing of the PNPO gene was undertaken for a cohort of 82 individuals who had shown a reduction in frequency and severity of seizures in response to pyridoxine or pyridoxal 5'-phosphate. Novel sequence changes were studied using a new cell-free expression system and a mass spectrometry-based assay for pyridoxamine phosphate oxidase. Three groups of patients with PNPO mutations that had reduced enzyme activity were identified: (i) patients with neonatal onset seizures responding to pyridoxal 5'-phosphate (n = 6); (ii) a patient with infantile spasms (onset 5 months) responsive to pyridoxal 5'-phosphate (n = 1); and (iii) patients with seizures starting under 3 months of age responding to pyridoxine (n = 8). Data suggest that certain genotypes (R225H/C and D33V) are more likely to result in seizures that to respond to treatment with pyridoxine. Other mutations seem to be associated with infertility, miscarriage and prematurity. However, the situation is clearly complex with the same combination of mutations being seen in patients who responded and did not respond to pyridoxine. It is possible that pyridoxine responsiveness in PNPO deficiency is affected by prematurity and age at the time of the therapeutic trial. Other additional factors that are likely to influence treatment response and outcome include riboflavin status and how well the foetus has been supplied with vitamin B6 by the mother. For some patients there was a worsening of symptoms on changing from pyridoxine to pyridoxal 5'-phosphate. Many of the mutations in PNPO affected residues involved in binding flavin mononucleotide or pyridoxal 5'-phosphate and many of them showed residual enzyme activity. One sequence change (R116Q), predicted to affect flavin mononucleotide binding and binding of the two PNPO dimers, and with high residual activity was found in Groups (ii) and (iii). This sequence change has been reported in the 1000 Genomes project suggesting it could be a polymorphism but alternatively it could be a common mutation, perhaps responsible for the susceptibility locus for genetic generalized epilepsy on 17q21.32 (close to rs72823592). We believe the reduction in PNPO activity and B6-responsive epilepsy in the patients reported here indicates that it contributes to the pathogenesis of epilepsy. ","dc:creator":"Mills PB","dc:date":"2014","dc:title":"Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome."}},"rdfs:label":"Mills Patient 9"},{"id":"cggv:9ac6f151-3d32-4d6c-90d8-da0eecbc88ca","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9ac6f151-3d32-4d6c-90d8-da0eecbc88ca_variant_evidence_item"},{"id":"cggv:9ac6f151-3d32-4d6c-90d8-da0eecbc88ca_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"D33V reduction of enzyme activity by ~55%."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:7cde0d76-ef44-4a5c-80cf-28246cdbce3b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7cde0d76-ef44-4a5c-80cf-28246cdbce3b","type":"Proband","allele":{"id":"cggv:fc68cfd3-6ee8-4bf5-8ee9-50c0f62bfa4a"},"detectionMethod":"DNA analysis from the chorionic villus indicated that the foetus was affected","firstTestingMethod":"Other","phenotypes":"obo:HP_0001250","sex":"UnknownEthnicity","variant":{"id":"cggv:2c7c267e-0068-40fe-b76d-308e2d8da8ba_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fc68cfd3-6ee8-4bf5-8ee9-50c0f62bfa4a"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24645144"},"rdfs:label":"Mills Patient 2"},{"id":"cggv:2c7c267e-0068-40fe-b76d-308e2d8da8ba","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:2c7c267e-0068-40fe-b76d-308e2d8da8ba_variant_evidence_item"},{"id":"cggv:2c7c267e-0068-40fe-b76d-308e2d8da8ba_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"D33V reduction of enzyme activity by ~55% ***R95H reduction in activity by 18% in CHO cells."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ec_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:881e719a-4ef0-4316-82b8-05a70b16aab2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:881e719a-4ef0-4316-82b8-05a70b16aab2","type":"Proband","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.674G>A (p.Arg225His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA354181"}},"detectionMethod":"ALDH7A1 normal sequence followed by single gene test for PNPO","firstTestingMethod":"Other","phenotypeFreeText":"desaturation, recurrent single breakthrough seizure during infancy","phenotypes":["obo:HP_0000496","obo:HP_0001263","obo:HP_0002133","obo:HP_0001336"],"sex":"UnknownEthnicity","variant":{"id":"cggv:901997f2-cb3f-4aaf-8df9-1ca4b3347c76_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24658933","type":"dc:BibliographicResource","dc:abstract":"To determine whether patients with pyridoxine-responsive seizures but normal biomarkers for antiquitin deficiency and normal sequencing of the ALDH7A1 gene may have PNPO mutations.","dc:creator":"Plecko B","dc:date":"2014","dc:title":"Pyridoxine responsiveness in novel mutations of the PNPO gene."}},"rdfs:label":"Patient 2b"},{"id":"cggv:901997f2-cb3f-4aaf-8df9-1ca4b3347c76","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:901997f2-cb3f-4aaf-8df9-1ca4b3347c76_variant_evidence_item"},{"id":"cggv:901997f2-cb3f-4aaf-8df9-1ca4b3347c76_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:18daf778-446a-46b1-b861-e878827a8cb7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:18daf778-446a-46b1-b861-e878827a8cb7","type":"Proband","allele":{"id":"cggv:046ccf56-9dfb-4a92-be8f-001eba725443","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.283C>T (p.Arg95Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1297019"}},"detectionMethod":"DNA analysis from the chorionic villus indicated that the foetus was affected","firstTestingMethod":"Other","phenotypeFreeText":"IQ 66 at 9 mo","phenotypes":["obo:HP_0000750","obo:HP_0001250","obo:HP_0008936"],"sex":"UnknownEthnicity","variant":{"id":"cggv:a6efc705-390c-4dc0-86ed-9dfa45de6f7b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:046ccf56-9dfb-4a92-be8f-001eba725443"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24645144"},"rdfs:label":"Mills Patient 5"},{"id":"cggv:a6efc705-390c-4dc0-86ed-9dfa45de6f7b","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a6efc705-390c-4dc0-86ed-9dfa45de6f7b_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5310c1cb-532c-49e3-bc3a-b92578500c2d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5310c1cb-532c-49e3-bc3a-b92578500c2d","type":"Proband","allele":[{"id":"cggv:be367505-5d25-4379-b0da-b52ac7e48ad2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.421C>T (p.Arg141Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8629191"}},{"id":"cggv:8e7f9b41-fcaf-43c8-a5e6-f436e075a1a3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.279_290del (p.Ala94_Leu97del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499214028"}}],"detectionMethod":"ALDH7A1 normal sequence followed by single gene test for PNPO","firstTestingMethod":"Other","phenotypes":["obo:HP_0002133","obo:HP_0001336","obo:HP_0000496"],"sex":"UnknownEthnicity","variant":[{"id":"cggv:1509df2a-7d63-4940-aa43-e3f4fab4cb20_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:8e7f9b41-fcaf-43c8-a5e6-f436e075a1a3"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24658933"},{"id":"cggv:544486e7-9335-4fe8-b2d2-222f06b4205c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:be367505-5d25-4379-b0da-b52ac7e48ad2"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24658933"}],"rdfs:label":"Patient 3"},{"id":"cggv:1509df2a-7d63-4940-aa43-e3f4fab4cb20","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1509df2a-7d63-4940-aa43-e3f4fab4cb20_variant_evidence_item"},{"id":"cggv:1509df2a-7d63-4940-aa43-e3f4fab4cb20_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del."}],"strengthScore":2},{"id":"cggv:544486e7-9335-4fe8-b2d2-222f06b4205c","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:544486e7-9335-4fe8-b2d2-222f06b4205c_variant_evidence_item"},{"id":"cggv:544486e7-9335-4fe8-b2d2-222f06b4205c_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:4b5c0852-ce99-46f8-9851-768be90442cf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:4b5c0852-ce99-46f8-9851-768be90442cf","type":"Proband","allele":{"id":"cggv:976920d6-a3a5-4496-be70-cc9260513aad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.148G>A (p.Glu50Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA316546"}},"detectionMethod":"DNA analysis from the chorionic villus indicated that the foetus was affected","firstTestingMethod":"Other","phenotypes":["obo:HP_0001263","obo:HP_0001250"],"sex":"UnknownEthnicity","variant":{"id":"cggv:d90beeef-71c0-455d-9659-23d910ce9adc_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:976920d6-a3a5-4496-be70-cc9260513aad"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24645144"},"rdfs:label":"Mills Patient 1"},{"id":"cggv:d90beeef-71c0-455d-9659-23d910ce9adc","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d90beeef-71c0-455d-9659-23d910ce9adc_variant_evidence_item"},{"id":"cggv:d90beeef-71c0-455d-9659-23d910ce9adc_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"E50K reduction of enzyme activity by 20% (previously no reduction of activity in CHO cells)  "}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ff2086aa-7e7d-4291-8e5f-65664a2cbe7a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ff2086aa-7e7d-4291-8e5f-65664a2cbe7a","type":"Proband","allele":{"id":"cggv:778540fe-d8c9-4040-827f-d01dd813d406","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.686G>A (p.Arg229Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA316568"}},"detectionMethod":"Unknown testing strategy","phenotypeFreeText":"elevated alkaline phosphate","phenotypes":["obo:HP_0012758","obo:HP_0200134","obo:HP_0000488","obo:HP_0001250"],"sex":"UnknownEthnicity","variant":{"id":"cggv:c41fe1ad-8739-4d38-9d47-d40080ec0ca9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:778540fe-d8c9-4040-827f-d01dd813d406"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28985901"},"rdfs:label":"Guerriero Patient 1"},{"id":"cggv:c41fe1ad-8739-4d38-9d47-d40080ec0ca9","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:c41fe1ad-8739-4d38-9d47-d40080ec0ca9_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:2274155d-b5aa-44af-bc38-0a329f721ff9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:2274155d-b5aa-44af-bc38-0a329f721ff9","type":"Proband","allele":{"id":"cggv:778540fe-d8c9-4040-827f-d01dd813d406"},"detectionMethod":"clinical gene panel","firstTestingMethod":"PCR","phenotypes":["obo:HP_0010851","obo:HP_0002487","obo:HP_0001252","obo:HP_0000580","obo:HP_0002266","obo:HP_0032833"],"sex":"UnknownEthnicity","variant":{"id":"cggv:92067ba3-1aaf-46a4-b3b2-f4469d3da9c7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:778540fe-d8c9-4040-827f-d01dd813d406"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28133863","type":"dc:BibliographicResource","dc:abstract":"We sought to identify genetic causes of early onset epileptic encephalopathies with burst suppression (Ohtahara syndrome and early myoclonic encephalopathy) and evaluate genotype-phenotype correlations.","dc:creator":"Olson HE","dc:date":"2017","dc:title":"Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression."}},"rdfs:label":"Patient 18"},{"id":"cggv:92067ba3-1aaf-46a4-b3b2-f4469d3da9c7","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:92067ba3-1aaf-46a4-b3b2-f4469d3da9c7_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:d00b6375-515f-4d6a-801f-4587a8d8902f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:d00b6375-515f-4d6a-801f-4587a8d8902f","type":"Proband","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff"},"detectionMethod":"Unknown testing strategy","phenotypeFreeText":"elevated alkaline phosphatase","phenotypes":["obo:HP_0001250","obo:HP_0012758","obo:HP_0200134"],"sex":"UnknownEthnicity","variant":{"id":"cggv:3d5583bf-4636-4435-be0e-5b6e59a52356_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28985901"},"rdfs:label":"Guerriero Patient 5"},{"id":"cggv:3d5583bf-4636-4435-be0e-5b6e59a52356","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:3d5583bf-4636-4435-be0e-5b6e59a52356_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:38edbd82-7008-4a6b-9243-7390ec4e3c98_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:38edbd82-7008-4a6b-9243-7390ec4e3c98","type":"Proband","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"detectionMethod":"ALDH7A1 normal sequencing followed by single gene test for PNPO","firstTestingMethod":"Other","phenotypes":["obo:HP_0001250","obo:HP_0001263","obo:HP_0000496","obo:HP_0001336","obo:HP_0000253","obo:HP_0001285"],"sex":"UnknownEthnicity","variant":{"id":"cggv:36fd4390-4f3b-4adb-9b24-bbf077ce4050_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24658933"},"rdfs:label":"Patient 4a"},{"id":"cggv:36fd4390-4f3b-4adb-9b24-bbf077ce4050","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:36fd4390-4f3b-4adb-9b24-bbf077ce4050_variant_evidence_item"},{"id":"cggv:36fd4390-4f3b-4adb-9b24-bbf077ce4050_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:4a54fa3c-649f-4722-b3c1-363d0d62014f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:4a54fa3c-649f-4722-b3c1-363d0d62014f","type":"Proband","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff"},"detectionMethod":"Unknown testing strategy","phenotypes":["obo:HP_0200134","obo:HP_0001250","obo:HP_0012758"],"sex":"UnknownEthnicity","variant":{"id":"cggv:14aca4fb-5794-4206-a2ac-a0e09277477a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28985901"},"rdfs:label":"Guerriero Patient 3"},{"id":"cggv:14aca4fb-5794-4206-a2ac-a0e09277477a","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:14aca4fb-5794-4206-a2ac-a0e09277477a_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:d5ad1230-cc75-4247-9f89-1cabd49d7263_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:d5ad1230-cc75-4247-9f89-1cabd49d7263","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":{"id":"cggv:a0ad5b34-177e-4f57-9044-b4357602ea9c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.784T>C (p.Ter262Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118330"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"sex":"Female","variant":{"id":"cggv:8a5726e2-24dd-4f28-8f70-1529c1f6903c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a0ad5b34-177e-4f57-9044-b4357602ea9c"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15772097","type":"dc:BibliographicResource","dc:abstract":"In the mouse, neurotransmitter metabolism can be regulated by modulation of the synthesis of pyridoxal 5'-phosphate and failure to maintain pyridoxal phosphate (PLP) levels results in epilepsy. This study of five patients with neonatal epileptic encephalopathy suggests that the same is true in man. Cerebrospinal fluid and urine analyses indicated reduced activity of aromatic L-amino acid decarboxylase and other PLP-dependent enzymes. Seizures ceased with the administration of PLP, having been resistant to treatment with pyridoxine, suggesting a defect of pyridox(am)ine 5'-phosphate oxidase (PNPO). Sequencing of the PNPO gene identified homozygous missense, splice site and stop codon mutations. Expression studies in Chinese hamster ovary cells showed that the splice site (IVS3-1g>a) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation (R229W) markedly reduced pyridox(am)ine phosphate oxidase activity. Maintenance of optimal PLP levels in the brain may be important in many neurological disorders in which neurotransmitter metabolism is disturbed (either as a primary or as a secondary phenomenon).","dc:creator":"Mills PB","dc:date":"2005","dc:title":"Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase."}},"rdfs:label":"Patient K1"},{"id":"cggv:8a5726e2-24dd-4f28-8f70-1529c1f6903c","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:8a5726e2-24dd-4f28-8f70-1529c1f6903c_variant_evidence_item"},{"id":"cggv:8a5726e2-24dd-4f28-8f70-1529c1f6903c_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Functional data from 2 publications indicating a reduction of 100% (Mills et al, 2005) and 88% (Mills et al, 2014) in protein expression."}],"strengthScore":1.5,"dc:description":"Homozygous nonsense variant with functional data from 2 publications indicating a reduction of 100% (Mills et al, 2005) and 88% (Mills et al, 2014) in protein expression. The Epilepsy GCEP upgraded to 3 points total for increased evidence for pathogenicity. Additionally this proband has a affected sibling."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:1178fc4c-b8fc-4dfc-a267-985e1121bbed_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:1178fc4c-b8fc-4dfc-a267-985e1121bbed","type":"Proband","allele":[{"id":"cggv:976920d6-a3a5-4496-be70-cc9260513aad"},{"id":"cggv:47dacd7a-9468-46ea-adc8-6bdee43aef7b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.364-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA354156"}}],"phenotypes":["obo:HP_0002181","obo:HP_0002133","obo:HP_0025116","obo:HP_0003394","obo:HP_0001252","obo:HP_0002104","obo:HP_0002406","obo:HP_0000252","obo:HP_0002533","obo:HP_0012758","obo:HP_0001250","obo:HP_0001903","obo:HP_0002098","obo:HP_0002240","obo:HP_0001942","obo:HP_0010819"],"sex":"Male","variant":[{"id":"cggv:c89b5ced-6752-4e2e-bf4a-2d5704ab4be5_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:47dacd7a-9468-46ea-adc8-6bdee43aef7b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15772097"},{"id":"cggv:67a215e8-0a5f-44f8-8156-fbe8365921de_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:976920d6-a3a5-4496-be70-cc9260513aad"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15772097"}],"rdfs:label":"Patient J2"},{"id":"cggv:67a215e8-0a5f-44f8-8156-fbe8365921de","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:67a215e8-0a5f-44f8-8156-fbe8365921de_variant_evidence_item"}],"strengthScore":0,"dc:description":"Assay unknown therefore, this score has been downgraded to 0 points."},{"id":"cggv:c89b5ced-6752-4e2e-bf4a-2d5704ab4be5","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:c89b5ced-6752-4e2e-bf4a-2d5704ab4be5_variant_evidence_item"}],"strengthScore":0,"dc:description":"Assay unknown therefore, this score has been downgraded to 0 points."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:7dd90074-4ee0-474a-952a-f626686e3037_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7dd90074-4ee0-474a-952a-f626686e3037","type":"Proband","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"detectionMethod":"ALDH7A1 normal sequence followed by single gene test for PNPO","firstTestingMethod":"Other","phenotypeFreeText":"cognitive deficit","phenotypes":["obo:HP_0005484","obo:HP_0001336","obo:HP_0001285","obo:HP_0000496"],"sex":"UnknownEthnicity","variant":{"id":"cggv:e6193f7c-0677-4568-8166-9332dfbf75fa_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24658933"},"rdfs:label":"Patient 6"},{"id":"cggv:e6193f7c-0677-4568-8166-9332dfbf75fa","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:e6193f7c-0677-4568-8166-9332dfbf75fa_variant_evidence_item"},{"id":"cggv:e6193f7c-0677-4568-8166-9332dfbf75fa_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"**Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del.Expression studies using transfected CHO cells showed a 51% reduction in enzyme activity."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:6a20e5b6-a929-467a-bc16-1601259001c8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:6a20e5b6-a929-467a-bc16-1601259001c8","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"detectionMethod":"SNP array followed by single gene test for PNPO","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Other","phenotypes":["obo:HP_0001336","obo:HP_0000496"],"sex":"Male","variant":{"id":"cggv:2da8ede4-d634-426c-8c37-201320480d13_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24266778","type":"dc:BibliographicResource","dc:abstract":"Pyridox(am)ine phosphate oxidase (PNPO) deficiency causes severe early infantile epileptic encephalopathy and has been characterized as responding to pyridoxal-5'-phosphate but not to pyridoxine. Two males with PNPO deficiency and novel PNPO mutations are reported and their clinical, metabolic, and video-electroencephalographic (EEG) findings described. The first child showed electro-clinical responses to pyridoxine and deterioration when pyridoxine was withheld. At last review, he has well-controlled epilepsy with pyridoxal-5'-phosphate monotherapy and an autism spectrum disorder. The second child had a perinatal middle cerebral artery infarct and a myoclonic encephalopathy. He failed to respond to pyridoxine but responded well to pyridoxal-5'-phosphate. At the age of 21Â months he has global developmental delay and hemiparesis but is seizure-free with pyridoxal-5'-phosphate monotherapy. Plasma and cerebrospinal fluid pyridoxamine levels were increased in both children during treatment with pyridoxine or pyridoxal-5'-phosphate. These observations indicate that differential responses to pyridoxine and pyridoxal-5'-phosphate treatment cannot be relied upon to diagnose PNPO deficiency. ","dc:creator":"Ware TL","dc:date":"2014","dc:title":"Typical and atypical phenotypes of PNPO deficiency with elevated CSF and plasma pyridoxamine on treatment."}},"rdfs:label":"Case 1"},{"id":"cggv:2da8ede4-d634-426c-8c37-201320480d13","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:2da8ede4-d634-426c-8c37-201320480d13_variant_evidence_item"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:695574c7-2506-47a6-8ca3-38b0e5a33ec2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:695574c7-2506-47a6-8ca3-38b0e5a33ec2","type":"Proband","allele":{"id":"cggv:b8a531ec-ba59-4e18-8b82-10b576ec2eb3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.685C>T (p.Arg229Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118329"}},"detectionMethod":"DNA analysis from the chorionic villus indicated that the foetus was affected","firstTestingMethod":"Other","sex":"UnknownEthnicity","variant":{"id":"cggv:036bf478-d6a0-4774-bab7-f4513b6f1692_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b8a531ec-ba59-4e18-8b82-10b576ec2eb3"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15772097"},"rdfs:label":"Patient G7"},{"id":"cggv:036bf478-d6a0-4774-bab7-f4513b6f1692","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:036bf478-d6a0-4774-bab7-f4513b6f1692_variant_evidence_item"}],"strengthScore":0.1,"dc:description":"This variant was identified in a fetus, affected and terminated during pregnancy. Parents were carriers. Deceased sibship 6 includes a first child born at 32 weeks and died at 21 days, triplets conceived via IVF born at 24 weeks and died at 1dol and 6 months, twin brothers conceived via IVF born at 29 weeks and died at 17 and 19 days. No phenotypic information available therefore, this score has been downgraded to 0 points."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e4d48dcb-66a0-407d-907e-7386127729d1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e4d48dcb-66a0-407d-907e-7386127729d1","type":"Proband","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff"},"detectionMethod":"Unknown testing strategy","phenotypes":["obo:HP_0001250","obo:HP_0012758","obo:HP_0200134"],"sex":"UnknownEthnicity","variant":{"id":"cggv:212b546f-d4ec-479f-9a8a-0fce43dac4ed_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:234ee2fd-54d0-448d-b690-d3798e8b2bff"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28985901"},"rdfs:label":"Guerriero Patient 4"},{"id":"cggv:212b546f-d4ec-479f-9a8a-0fce43dac4ed","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:212b546f-d4ec-479f-9a8a-0fce43dac4ed_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3241945e-7fb5-4217-ba2c-0dad9d1d0b95_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3241945e-7fb5-4217-ba2c-0dad9d1d0b95","type":"Proband","allele":{"id":"cggv:2e5429e0-4756-43a1-bf30-fefddb44f608","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.347G>A (p.Arg116Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA154714"}},"detectionMethod":"DNA analysis from the chorionic villus indicated that the foetus was affected","firstTestingMethod":"Other","phenotypes":["obo:HP_0001328","obo:HP_0001250"],"sex":"UnknownEthnicity","variant":{"id":"cggv:d0e607f6-c932-44ab-b66b-bd499b1db799_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2e5429e0-4756-43a1-bf30-fefddb44f608"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24645144"},"rdfs:label":"Mills Patient 8"},{"id":"cggv:d0e607f6-c932-44ab-b66b-bd499b1db799","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:d0e607f6-c932-44ab-b66b-bd499b1db799_variant_evidence_item"}],"strengthScore":0,"dc:description":"Too high frequency in gnomAD = 525 homozygotes (gnomAD v2.1.1)"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:9e71d49b-4484-4965-830f-b5f6b22603e2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:9e71d49b-4484-4965-830f-b5f6b22603e2","type":"Proband","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"detectionMethod":"ALDH7A1 normal sequence followed by single gene test for PNPO","phenotypes":["obo:HP_0000496","obo:HP_0032816","obo:HP_0001263"],"sex":"Male","variant":{"id":"cggv:8b1dbd08-5e73-4e67-9e5d-bdbd5d9274ce_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24658933"},"rdfs:label":"Patient 1b"},{"id":"cggv:8b1dbd08-5e73-4e67-9e5d-bdbd5d9274ce","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:8b1dbd08-5e73-4e67-9e5d-bdbd5d9274ce_variant_evidence_item"},{"id":"cggv:8b1dbd08-5e73-4e67-9e5d-bdbd5d9274ce_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:7acfd9a7-b15b-49a8-9ed2-c0c9f1fc543f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7acfd9a7-b15b-49a8-9ed2-c0c9f1fc543f","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":{"id":"cggv:7c0e9a47-93ba-41d2-b732-e783a912e675","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.284G>A (p.Arg95His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/849386"}},"detectionMethod":"PNPO targeted sequencing","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Other","phenotypes":["obo:HP_0000470","obo:HP_0032794","obo:HP_0002557","obo:HP_0000426","obo:HP_0000218"],"sex":"Female","variant":{"id":"cggv:66daca41-3ca1-4bef-805b-62a5585935b1_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7c0e9a47-93ba-41d2-b732-e783a912e675"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18485777","type":"dc:BibliographicResource","dc:abstract":"The rare autosomal recessive disorder pyridoxine 5'-phosphate oxidase (PNPO) deficiency is a recently described cause of neonatal and infantile seizures. Clinical evaluation, and biochemical and genetic testing, were performed on a neonate with intractable seizures who did not respond to anticonvulsant drugs and pyridoxine. Sequencing of the PNPO gene revealed a novel homozygous c.284G>A transition in exon 3, resulting in arginine to histidine substitution and reduced activity of the PNPO mutant to 18% relative to the wild type. This finding enabled molecular prenatal diagnosis in a subsequent pregnancy, accurate genetic counseling in the large inbred family, and population screening.","dc:creator":"Khayat M","dc:date":"2008","dc:title":"PNPO deficiency: an under diagnosed inborn error of pyridoxine metabolism."}},"rdfs:label":"Patient IV3"},{"id":"cggv:66daca41-3ca1-4bef-805b-62a5585935b1","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:66daca41-3ca1-4bef-805b-62a5585935b1_variant_evidence_item"},{"id":"cggv:66daca41-3ca1-4bef-805b-62a5585935b1_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"R95H reduction in expression by 18% in CHO"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:403c29e4-684e-4048-b622-7888eba6b01f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:403c29e4-684e-4048-b622-7888eba6b01f","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":{"id":"cggv:778540fe-d8c9-4040-827f-d01dd813d406"},"detectionMethod":"SNP array followed by single gene test for PNPO","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0032794","obo:HP_0000496","obo:HP_0032816"],"sex":"Male","variant":{"id":"cggv:cfde8988-0b31-457b-92bd-57d1f8d41ade_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:778540fe-d8c9-4040-827f-d01dd813d406"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24266778"},"rdfs:label":"Case 2"},{"id":"cggv:cfde8988-0b31-457b-92bd-57d1f8d41ade","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:cfde8988-0b31-457b-92bd-57d1f8d41ade_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3de28163-eca9-4eb8-84e0-b1348c582d55_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3de28163-eca9-4eb8-84e0-b1348c582d55","type":"Proband","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"detectionMethod":"ALDH7A1 normal sequence followed by single gene test for PNPO","firstTestingMethod":"Other","phenotypeFreeText":"seizure free over 7 months at age 6","phenotypes":["obo:HP_0001336","obo:HP_0000496"],"sex":"UnknownEthnicity","variant":{"id":"cggv:3f54c3dd-b4ce-4807-a54d-67380e997f23_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24658933"},"rdfs:label":"Patient 7"},{"id":"cggv:3f54c3dd-b4ce-4807-a54d-67380e997f23","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:3f54c3dd-b4ce-4807-a54d-67380e997f23_variant_evidence_item"},{"id":"cggv:3f54c3dd-b4ce-4807-a54d-67380e997f23_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del.Expression studies using transfected CHO cells showed a 51% reduction in enzyme activity."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:40fc6103-7df8-47f8-95df-8b771b1d1bd0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:40fc6103-7df8-47f8-95df-8b771b1d1bd0","type":"Proband","allele":{"id":"cggv:ad571250-0016-4652-a326-c474cf15d560","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.352G>A (p.Gly118Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA400057365"}},"detectionMethod":"PNPO Targeted sequencing","firstTestingMethod":"Other","phenotypes":["obo:HP_0032807","obo:HP_0000737","obo:HP_0000496","obo:HP_0012758","obo:HP_0001252"],"sex":"Male","variant":{"id":"cggv:0a2e9cea-d87d-4507-ab5e-a1d4b1a71cf2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:ad571250-0016-4652-a326-c474cf15d560"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23430561","type":"dc:BibliographicResource","dc:abstract":"Autosomal-recessive pyridox(am)ine phosphate oxidase (PNPO) deficiency causes pyridoxal-5-phosphate (PLP)-dependent epilepsy. We describe partial PNPO deficiency with a transient response to pyridoxine (B6).","dc:creator":"Pearl PL","dc:date":"2012","dc:title":"Partial Pyridoxine Responsiveness in PNPO Deficiency."}},"rdfs:label":"Male"},{"id":"cggv:0a2e9cea-d87d-4507-ab5e-a1d4b1a71cf2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:0a2e9cea-d87d-4507-ab5e-a1d4b1a71cf2_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ce459aa3-62a1-4c21-b05a-1e6c1c773eec_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ce459aa3-62a1-4c21-b05a-1e6c1c773eec","type":"Proband","ageType":"AgeAtReport","ageUnit":"Months","ageValue":12,"allele":{"id":"cggv:c6daec59-e62b-4469-a7b8-74e5531d3bd7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018129.4(PNPO):c.448_451del (p.Pro150fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA208971"}},"phenotypeFreeText":"neonatal onset seizures","phenotypes":"obo:HP_0001250","sex":"Female","variant":{"id":"cggv:849213c0-cb06-4097-b6cd-1174297d8e2c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c6daec59-e62b-4469-a7b8-74e5531d3bd7"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25296925","type":"dc:BibliographicResource","dc:abstract":"Pyridox(am)ine-5-phosphate oxidase deficiency is an autosomal recessive disorder of pyridoxine metabolism. Intractable neonatal epileptic encephalopathy is the classical presentation. Pyridoxal-5-phosphate or pyridoxine supplementation improves symptoms. We report a patient with myoclonic and tonic seizures at the age of 1 hour. Pyridoxal-5-phosphate was started on the first day of life and seizures stopped at the age of 3 days, but encephalopathy persisted for 4 weeks. She had normal neurodevelopmental outcome at the age of 12 months on pyridoxal-5-phosphate monotherapy. She had novel homozygous pathogenic frameshift mutation (c.448_451del;p.Pro150Argfs*27) in the PNPO gene. Long-lasting encephalopathy despite well-controlled clinical seizures does neither confirm nor exclude pyridox(am)ine-5-phosphate oxidase deficiency. Normal neurodevelopmental outcome of our patient emphasizes the importance of pyridoxal-5-phosphate treatment. Pyridox(am)ine-5-phosphate oxidase deficiency should be included in the differential diagnosis of Ohtahara syndrome and neonatal myoclonic encephalopathy as a treatable underlying cause. In addition, we reviewed the literature for pyridox(am)ine-5-phosphate oxidase deficiency and summarized herein all confirmed cases. ","dc:creator":"Guerin A","dc:date":"2015","dc:title":"Pyridox(am)ine-5-Phosphate Oxidase Deficiency Treatable Cause of Neonatal Epileptic Encephalopathy With Burst Suppression: Case Report and Review of the Literature."}},"rdfs:label":"Guerin Patient"},{"id":"cggv:849213c0-cb06-4097-b6cd-1174297d8e2c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:849213c0-cb06-4097-b6cd-1174297d8e2c_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:2d481a9c-115f-4859-9003-0a7a0f23dc41_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:2d481a9c-115f-4859-9003-0a7a0f23dc41","type":"Proband","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"detectionMethod":"ALDH7A1 normal sequence followed by single gene test for PNPO","firstTestingMethod":"Other","phenotypes":["obo:HP_0002317","obo:HP_0001336","obo:HP_0000496"],"sex":"UnknownEthnicity","variant":{"id":"cggv:5a549fa1-1d85-4e8b-b54e-fbeea5625531_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fdf2e1e3-53b5-44de-9d50-58f65c194c3c"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24658933"},"rdfs:label":"Patient 5"},{"id":"cggv:5a549fa1-1d85-4e8b-b54e-fbeea5625531","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:5a549fa1-1d85-4e8b-b54e-fbeea5625531_variant_evidence_item"},{"id":"cggv:5a549fa1-1d85-4e8b-b54e-fbeea5625531_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Expression studies using transfected CHO cells showed undetectable enzyme activity for R225H; a reduction of activity by 51% for Arg141Cys and undetectable activity for p.Ala94_Leu97del."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ec_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ec_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:d175da31-165b-47ee-bb64-ea0cef6971e5","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:118cc404-7e49-4418-ad40-be8a83e0817b","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31616300","type":"dc:BibliographicResource","dc:abstract":"Neonatal epileptic encephalopathy (NEE), as a result of pyridoxine 5'-phosphate oxidase (PNPO) deficiency, is a rare neural disorder characterized by intractable seizures and usually leads to early infant death. The clinical phenotypes do not respond to antiepileptic drugs but are alleviated in most cases by giving large doses of pyridoxal 5'-phosphate (PLP). PLP is the active form of vitamin B6 participating in more than 100 enzymatic pathways. One of the causes of NEE is pathogenic mutations in the gene for human ","dc:creator":"Chen PY","dc:date":"2019","dc:title":"Pyridoxamine Supplementation Effectively Reverses the Abnormal Phenotypes of Zebrafish Larvae With PNPO Deficiency."},"rdfs:label":"Rescue with zpnpo and hPNPO mRNA"}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":0,"dc:description":"downgraded to 0 points because it is a vertebrate, non-mammalian and did not actually assess the phenotypes observed in humans with variants in PNPO and pyridoxal phosphate-responsive seizures"},{"id":"cggv:ff8ebfb8-e3a9-467c-bb06-d64427e38975","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:52c4aa3f-768d-4fdd-ac45-afc85e15d3e8","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"locomotion analysis used to show pnpo-/- zebrafish developing sizures","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31759955","type":"dc:BibliographicResource","dc:abstract":"Pyridox(am)ine 5'-phosphate oxidase (PNPO) catalyzes oxidation of pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) to pyridoxal 5'-phosphate (PLP), the active form of vitamin B","dc:creator":"Ciapaite J","dc:date":"2020","dc:title":"Pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency in zebrafish results in fatal seizures and metabolic aberrations."},"rdfs:label":"Pnpo deficient zebrafish"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"downgraded to 1 point because it is a zebrafish model without electrophysical correction"},{"id":"cggv:97965492-7f31-4788-b6f6-8d3ac18f47b8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:4f03ab76-bd82-4912-9dcb-d60ee79dbd46","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Both lethality are associated with low PLP levels and can be rescued by ubiquitous expression of wild-type sgll and hPNPO, suggesting functional conservation of PNPO between human and flies. Sgll95 homozygotes reared on sugar-only diet exhibit lethal phenotype (100%) vs wildtype (sgll95 5-day vs sgll KD 4-day survival). Cell-type specific expression sgll KD demonstrate PNPO in brain is necessary for seizure prevention/survival.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31261385","type":"dc:BibliographicResource","dc:abstract":"Pyridox (am) ine 5'-phosphate oxidase (PNPO) is a rate-limiting enzyme in converting dietary vitamin B6 (VB6) to pyridoxal 5'-phosphate (PLP), the biologically active form of VB6 and involved in the synthesis of neurotransmitters including Î³-aminobutyric acid (GABA), dopamine, and serotonin. In humans, PNPO mutations have been increasingly identified in neonatal epileptic encephalopathy and more recently also in early-onset epilepsy. Till now, little is known about the neurobiological mechanisms underlying PNPO-deficiency-induced seizures due to the lack of animal models. Previously, we identified a c.95 C>A missense mutation in sugarlethal (sgll)-the Drosophila homolog of human PNPO (hPNPO)-and found mutant (sgll95) flies exhibiting a lethal phenotype on a diet devoid of VB6. Here, we report the establishment of both sgll95 and ubiquitous sgll knockdown (KD) flies as valid animal models of PNPO-deficiency-induced epilepsy. Both sgll95 and sgll KD flies exhibit spontaneous seizures before they die. Electrophysiological recordings reveal that seizures caused by PNPO deficiency have characteristics similar to that in flies treated with the GABA antagonist picrotoxin. Both seizures and lethality are associated with low PLP levels and can be rescued by ubiquitous expression of wild-type sgll or hPNPO, suggesting the functional conservation of the PNPO enzyme between humans and flies. Results from cell type-specific sgll KD further demonstrate that PNPO in the brain is necessary for seizure prevention and survival. Our establishment of the first animal model of PNPO deficiency will lead to better understanding of VB6 biology, the PNPO gene and its mutations discovered in patients, and can be a cost-effective system to test therapeutic strategies.","dc:creator":"Chi W","dc:date":"2019","dc:title":"Pyridox (am) ine 5'-phosphate oxidase deficiency induces seizures in Drosophila melanogaster."},"rdfs:label":"PNPO in Brain is Necessary for Seizure Prevention"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"Downgraded to 1 point because it is a non-mammalian model system."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2}],"evidenceStrength":"Definitive","sequence":3593,"specifiedBy":"GeneValidityCriteria8","strengthScore":14,"subject":{"id":"cggv:78de7402-400d-4c0f-96ba-6ae9c4b1bada","type":"GeneValidityProposition","disease":"obo:MONDO_0012407","gene":"hgnc:30260","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"PNPO was first reported in relation to autosomal recessive pyridoxal phosphate-responsive seizures in 2005 (Mills et al., 2005, PMID: 15772097). Pyridoxal phosphate-responsive seizures (MONDO: 0012407) is characterized by neonatal-onset severe seizures commonly observed within the first several hours to days of life, and subsequent encephalopathy. Developmental delay, intellectual disability, hypotonia, erratic eye movements, etc are also observed in patients with variants in PNPO. Fourteen variants (missense and frameshift) that have been reported in twenty-six probands in nine publications (PMIDs: 15772097, 23430561, 18485777, 24266778, 24658933, 24645144, 25296925, 28133863, 28985901) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. This gene-disease association is also supported by animal models and a rescue (PMIDs: 15772097, 31261385, 31616300, 31759955). Chi et al., 2019 (PMID: 31261385) demonstrated cell-type specific expression in sugarlethal drosophila with the previously identified variant c.95C>A is a valid model for PNPO-deficiency induced epilepsy. Ciapaite et al., 2020 (PMID: 31759955) used CRISPR/Cas9 gene editing to generate Pnpo-deficient zebrafish in which locomotion analysis demonstrated that these zebrafish developed seizures and only 38% survived. Even though the default points for animal models is 2 points, the ClinGen Epilepsy GCEP has decided to downgrade evidence in Chi et al., 2019 and Ciapaite et al., 2020 to 1 point because they are non-mammalian model systems. An additional line of experimental evidence (rescue) was published by Chen et al., 2019 (PMID: 31616300). In summary, PNPO is definitively associated with autosomal recessive pyridoxal phosphate-responsive seizures. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Epilepsy Gene Curation Expert Panel on 12/15/2020 (SOP Version 8).","dc:isVersionOf":{"id":"cggv:f3ff7b38-dd26-458a-afbb-4870785c42ec"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}